Coley's toxins (also called Coley's toxin, [1] Coley's vaccine, [2] Coley vaccine, Coley's fluid or mixed bacterial vaccine) is a mixture containing toxins filtered from killed bacteria of species Streptococcus pyogenes and Serratia marcescens , named after William Coley, a surgical oncologist at the Hospital for Special Surgery who developed the mixture in the late 19th century as a treatment for cancer. [3]
Their use in the late nineteenth and early 20th centuries represented a precursor to modern cancer immunotherapy, although at that time their mechanism of action was not completely understood. [4]
There is no evidence that Coley's toxins have any effectiveness in treating cancer, and use of them risks causing serious harm. [5]
 | This article's factual accuracy is disputed .(November 2023) |
According to Cancer Research UK, "available scientific evidence does not currently support claims that Coley's toxins can treat or prevent cancer". [5] People with cancer who take Coley's toxins alongside conventional cancer treatments, or who use it as a substitute for those treatments, risk seriously harming their health. [5]
Bacterial immunotherapy for the treatment of cancer has been utilized throughout history, with the earliest cases going back to c. 2600 BC. [6] Egyptian physician Imhotep treated tumors by a poultice, followed by incision, to facilitate the development of infection in the desired location and cause regression of the tumors. In 13th century, St. Peregrine experienced spontaneous regression of tumor, after the tumor became infected. In the 18th and 19th centuries, deliberate infection of tumors was a standard treatment, whereby surgical wounds were left open to facilitate the development of infection. Throughout the time period, physicians reported successful treatment of cancer by exposing the tumor to infection including the report of French physician Dussosoy who covered an ulcerated breast carcinoma with gangrenous discharge soaked cloth, resulting in disappearance of tumor. [7] [8] [9] Observations of a relationship between infection and cancer regression date back to at least the 18th century. [10] [11] More specifically, observations of an apparent relationship between erysipelas and remission of cancer predate Coley. [12] For example, Anton Chekhov, in his capacity as a physician, recorded such a relationship in 1884. [13]
Coley started his investigations after the death of one of his first patients, Elizabeth Dashiell, from sarcoma. Dashiell was a close childhood friend of John D. Rockefeller Jr., who later indicated that her death was what first motivated his subsequent funding of cancer research. [14] [4]
Frustrated by this case, Coley's subsequent research led him to announce evidence of the apparent relationship between infection and cancer regression, which he published in 1891. [15] His initial attempts at deliberate infection were mixed, [16] but in 1893 he began combining Streptococcus pyogenes and Serratia marcescens , based upon research from G.H. Roger indicating that this combination led to greater virulence. [17]
Coley published the results of his work as a case series, making it difficult to interpret them with confidence. According to the American Cancer Society, "more research would be needed to determine what benefit, if any, this therapy might have for people with cancer". [18]
The so-called Coley's toxins were used against different types of cancer from the year 1893 [19] through the year 1963. Within the preparation's first decade, it was changed from an unfiltered mixture of killed bacteria to a porcelain-filtered mixture, [4] which reduced the adverse effect profile. [4] From 1923 on, Parke-Davis was the only commercial source of Coley's toxins in the United States. Hall (1997) [4] explains that the versions used by Coley himself were custom-compounded, although the formula for the preparation was never standardized. [20]
In the wake of the thalidomide controversy and the Kefauver Harris Amendment of 1962, Coley's toxins were assigned "new drug" status by the Food and Drug Administration (FDA), making it illegal to prescribe them outside of clinical trials. [21] Since then, several small clinical trials have been conducted with mixed results. [22]
Coley's toxins were also produced by the small German pharmaceutical company Südmedica [23] and sold under the trade name Vaccineurin. [24] However, production ceased by 1990 because of a lack of re-approval by German Federal Institute for Drugs and Medical Devices.
There were multiple rationales proposed for how Coley's toxins might work.
One rationale argues that macrophages are either in "repair mode", furthering the growing of cancer, or in "defense mode", destroying cancer. However, macrophages are in "defense mode" only if there is some recognized enemy. As cancer tissue is not recognized as enemy (but as normal body tissue), there is a need to bring more macrophages into "defense mode" by simulating an infection. The simulated infection results in a real fever. Unlike hyperthermia, real fever not only means heating of the body but also higher activity of the immune system. Thus, fever is seen as a precondition for a therapy using Coley's Toxins to succeed. [10] [25] [26]
One of the agents in Coley's Toxin that is thought to be biologically active is a lipopolysaccharide which causes fever. [27] The resulting fever from the lipopolysaccharide is thought to increase lymphocyte activity and boosts tumor necrosis factor (TNF). Tsung and Norton in Surgical Oncology reported that the active agent was thought to be interleukin-12, rather than TNF. [28]
Another hypothesis argues that streptokinase (produced by killed bacteria of species Streptococcus pyogenes together with plasminogen from the patient) is the active agent of Coley's toxins. [29] [30] This hypothesis is supported by the fact that streptokinase has been associated with successful treatment of thromboangiitis obliterans. [31]
A robust fever, which occurs in response to Coley fluid, generates inflammatory factors with co-stimulatory activity, which activate resting dendritic cells (DC), leading to the activation of anergic T cells, possibly accomplished through a second process, where physical damage to cancer cells leads to a sudden supply of cancer antigens to the dendritic cell population. [10] [25]
A private biotech company, Coley Pharmaceutical Group, has conducted clinical trials using genetic sequences which may have contributed to Coley's toxin's effectiveness, and was acquired by Pfizer in January 2008. [32] In addition, the Waisbren Clinic in Wisconsin reports they have used Coley's toxin to treat patients since 1972. [33] Coley's toxins are generally not available where approval or licence is required (in particular in the United States and Germany).
Drug makers including Pfizer and Sanofi-Aventis are interested in modern versions of Coley's toxins; [34] Pfizer has acquired the Coley Pharmaceutical Group, set up in 1997 [35]
Some specialized medical doctors in Germany apply Coley's toxins to patients. They can do so legally because, in Germany, unapproved medications may be produced, although they may not be sold or given away. Physicians can go to special laboratories and produce Coley's toxins there using their own hands. Coley's toxins may still be applied by a licensed medical doctor, because in Germany there is " Therapiefreiheit " ("therapy freedom"), the legal right to apply whichever therapy a physician considers to be appropriate in the light of their medical knowledge. For example, Dr Josef Issels used several unconventional and controversial treatments, including Coley's toxins, for cancer patients in the second half of the 20th century.
This kind of therapy is offered as "Fiebertherapie" (fever therapy) or better "Aktive Fiebertherapie" (active fever therapy). This term was introduced by E. Göhring in 1985. [36] Hyperthermia therapy or thermotherapy is not the same type of treatment, although sometimes incorrectly called "fever therapy".[ citation needed ]
According to an article in the Iowa Orthopedic Journal, Coley's toxins were opposed by the medical establishment despite his reports of good results, because his reports were not believed to be credible. [37] Hall (1997) [4] extensively explores the issue; one of the lenses through which Hall explores it is the decades-long, complicated relationship of James Ewing and William Coley as colleagues at the same institution. Hall explains that the aspects of Coley's work that were scientifically underpowered—the anecdotal emphasis, the lack of a standardized formula for the toxins preparations, the lack of methodologically rigorous clinical trials, and (relatedly) the problem of poor replicability—led many scientists to dismiss all use of Coley's toxins as mere hogwash. Although the truth was more complex than that dismissal recognized, it is a fact that the toxins never made it to the stage of a safe and effective medication, and today their use as alternative medicine is clearly flawed for the same reason that malariotherapy as alternative medicine is flawed, given what humanity now knows about molecular biology that was not known when these older therapies were tried: Even if certain kinds of immune challenge or immunomodulation can produce desirable immunotherapeutic effects, these crude methods of inducing such challenge or modulation are not specific enough (not targeted enough), present too many harms, and do not work consistently enough to bring benefits to most patients, being dependent on idiotypic molecular factors (which were not understood at all when the therapies were first developed and which even today are still not easy for immunotherapy designers to deal with).
Streptococcal pharyngitis, also known as streptococcal sore throat, is pharyngitis caused by Streptococcus pyogenes, a gram-positive, group A streptococcus. Common symptoms include fever, sore throat, red tonsils, and enlarged lymph nodes in the front of the neck. A headache and nausea or vomiting may also occur. Some develop a sandpaper-like rash which is known as scarlet fever. Symptoms typically begin one to three days after exposure and last seven to ten days.
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immunotherapy is under preliminary research for its potential to treat various forms of cancer.
A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.
Spontaneous remission, also called spontaneous healing or spontaneous regression, is an unexpected improvement or cure from a disease that usually progresses. These terms are commonly used for unexpected transient or final improvements in cancer. Spontaneous remissions concern cancers of the haematopoietic system, while spontaneous regressions concern palpable tumors; however, both terms are often used interchangeably.
Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.
Tigecycline, sold under the brand name Tygacil, is a tetracycline antibiotic medication for a number of bacterial infections. It is a glycylcycline class drug that is administered intravenously. It was developed in response to the growing rate of antibiotic resistant bacteria such as Staphylococcus aureus, Acinetobacter baumannii, and E. coli. As a tetracycline derivative antibiotic, its structural modifications has expanded its therapeutic activity to include Gram-positive and Gram-negative organisms, including those of multi-drug resistance.
William Bradley Coley was an American bone surgeon and cancer researcher best known for his early contributions to the study of cancer immunotherapy, specifically causing infection as a way to fight cancer, a practice used as far back as 1550 BC. His work was not proven effective in his lifetime, and today Coley's toxins are known to be both ineffective and potentially harmful. Coley is nevertheless recognized as the Father of Cancer Immunotherapy for his contributions to the science.
The following are notable events in the Timeline of immunology:
Steven A. Rosenberg is an American cancer researcher and surgeon, chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. He pioneered the development of immunotherapy that has resulted in the first effective immunotherapies and the development of gene therapy. He is the first researcher to successfully insert foreign genes into humans.
Hyperthermia therapy(or hyperthermia, or thermotherapy) is a type of medical treatment in which body tissue is exposed to temperatures above body temperature, in the region of 40–45 °C (104–113 °F). Hyperthermia is usually applied as an adjuvant to radiotherapy or chemotherapy, to which it works as a sensitizer, in an effort to treat cancer.
Perianal cellulitis, also known as perianitis or perianal streptococcal dermatitis, is a bacterial infection affecting the lower layers of the skin (cellulitis) around the anus. It presents as bright redness in the skin and can be accompanied by pain, difficulty defecating, itching, and bleeding. This disease is considered a complicated skin and soft tissue infection (cSSTI) because of the involvement of the deeper soft tissues.
Neuvenge, Lapuleucel-T, is a therapeutic cancer vaccine (TCV) in development by Dendreon (DNDN). It uses the "immunotherapy platform approach" first successfully demonstrated on the U.S. Food and Drug Administration (FDA)-approved TCV Provenge. It was first tested on breast cancer patients with tumors expressing HER2/neu, and is now scheduled to be tested on bladder cancer patients.
Friedrich Fehleisen (1854–1924) was a German surgeon whose work focused on streptococcal bacteria. Dr. Fehleisen's work played a necessary role in the eventual uncovering of the etiology of many streptococcal illnesses. He made integral contributions to modern medicine's understanding of the Streptococcus pyogenes organism. He was born in Reutlingen, Württemberg, in 1854, and died in San Francisco, California, in 1924.
CRM197 is a non-toxic mutant of diphtheria toxin, currently used as a carrier protein for polysaccharides and haptens to make them immunogenic. There is some dispute about the toxicity of CRM197, with evidence that it is toxic to yeast cells and some mammalian cell lines.
PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitor anticancer drugs that block the activity of PD-1 and PDL1 immune checkpoint proteins present on the surface of cells. Immune checkpoint inhibitors are emerging as a front-line treatment for several types of cancer.
Cryoimmunotherapy, also referred to as cryoimmunology, is an oncological treatment for various cancers that combines cryoablation of tumor with immunotherapy treatment. In-vivo cryoablation of a tumor, alone, can induce an immunostimulatory, systemic anti-tumor response, resulting in a cancer vaccine—the abscopal effect. Thus, cryoablation of tumors is a way of achieving autologous, in-vivo tumor lysate vaccine and treat metastatic disease. However, cryoablation alone may produce an insufficient immune response, depending on various factors, such as high freeze rate. Combining cryotherapy with immunotherapy enhances the immunostimulating response and has synergistic effects for cancer treatment.
This is a historical timeline of the development and progress of cancer treatments, which includes time of discovery, progress, and approval of the treatments.
Bacterial therapy is the therapeutic use of bacteria to treat diseases. Bacterial therapeutics are living medicines, and may be wild type bacteria or bacteria that have been genetically engineered to possess therapeutic properties that is injected into a patient. Other examples of living medicines include cellular therapeutics, activators of anti-tumor immunity, or synergizing with existing tools and approaches. and phage therapeutics, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches.
Tumor-homing bacteria are facultative or obligate anaerobic bacteria that are able to target cancerous cells in the body, suppress tumor growth and survive in the body for a long time even after the infection. When this type of bacteria is administered into the body, it migrates to the cancerous tissues and starts to grow, and then deploys distinct mechanisms to destroy solid tumors. Each bacteria species uses a different process to eliminate the tumor. Some common tumor homing bacteria include Salmonella, Clostridium, Bifidobacterium, Listeria, and Streptococcus. The earliest research of this type of bacteria was highlighted in 1813 when scientists began observing that patients that had gas gangrene, an infection caused by the bacteria Clostridium, were able to have tumor regressions.
Uğur Şahin is a German oncologist and immunologist. He is the founder and CEO of BioNTech, which developed one of the major vaccines against COVID-19. His main fields of research are cancer research and immunology.